£470K
The seed round was led by Quantum Exponential Group and Evenlode Impact to support diagnostic imaging development.
"The closing of Siloton’s first round of investment represents a new chapter in the company’s history. We have a strong management team with world-leading technical know-how. This knowledge is complemented by the considerable expertise contained within our investor base; including clinical, sector, and commercial experts. We are all deeply excited to begin working together and building a compelling product for patients with age-related macular degeneration"